Abstract:Although treatment modalities for head and neck cancer have evolved considerably over the past decades, survival rates have plateaued. The treatment options remained limited to definitive surgery, surgery followed by fractionated radiotherapy with optional chemotherapy, and a definitive combination of fractionated radiotherapy and chemotherapy. Lately, immunotherapy has been introduced as the fourth modality of treatment, mainly administered as a single checkpoint inhibitor for recurrent or metastatic disease. While other regimens and combinations of immunotherapy and targeted therapy are being tested in clinical trials, adapting the appropriate regimens to patients and predicting their outcomes have yet to reach the clinical setting. Radiotherapy is mainly regarded as a means to target cancer cells while minimizing the unwanted peripheral effect. Radiotherapy regimens and fractionation are designed to serve this purpose, while the systemic effect of radiation on the immune response is rarely considered a factor while designing treatment. To bridge this gap, this review will highlight the effect of radiotherapy on the tumor microenvironment locally, and the immune response systemically. We will review the methodology to identify potential targets for therapy in the tumor microenvironment and the scientific basis for combining targeted therapy and radiotherapy. We will describe a current experience in preclinical models to test these combinations and propose how challenges in this realm may be faced. We will review new players in targeted therapy and their utilization to drive immunogenic response against head and neck cancer. We will outline the factors contributing to head and neck cancer heterogeneity and their effect on the response to radiotherapy. We will review in-silico methods to decipher intertumoral and intratumoral heterogeneity and how these algorithms can predict treatment outcomes. We propose that (a) the sequence of surgery, radiotherapy, chemotherapy, and targeted therapy should be designed not only to annul cancer directly, but to prime the immune response. (b) Fractionation of radiotherapy and the extent of the irradiated field should facilitate systemic immunity to develop. (c) New players in targeted therapy should be evaluated in translational studies toward clinical trials. (d) Head and neck cancer treatment should be personalized according to patients and tumor-specific factors.

Radiation oncology for the rhinologist

Oncology for the rhinologist

Current controversies in radiotherapy for nasopharyngeal carcinoma (NPC)

Reirradiation of locally recurrent nasopharyngeal cancer: history, advances, and promises for the future

A Systematic Review of Proton Therapy for the Management of Nasopharyngeal Cancer

Proton therapy for head and neck cancer: expanding the therapeutic window

Management of recurrent nasopharyngeal carcinoma: current perspectives

Feasibility of lattice radiotherapy using proton and carbon-ion pencil beam for sinonasal malignancy

Sinonasal Side Effects of Chemotherapy and/or Radiation Therapy for Head and Neck Cancer: A Literature Review

International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma

Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders

Re-irradiation with Moderate Hypo-fractionation Using Intensity Modulated Photon or Proton Radiation Therapy in Locally Recurrent Squamous Cell Carcinoma of Nasopharynx

Progress and emerging strategies to preserve function in the treatment of sinonasal cancer

Treatment and related morbidity of nasal cavity and paranasal sinus cancers

Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma

Combining Radiotherapy and Immunotherapy in Head and Neck Cancer

Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists

The role of carbon-ion radiotherapy in the treatment of adenoid cystic carcinoma of the nasopharynx

Future of Radiotherapy in Nasopharyngeal Carcinoma

Non-conventional Fractionated Radiotherapy for Nasopharyngeal Carcinoma

The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer